These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11674879)

  • 1. Does adding estrogen to the hormone-free days of an oral contraceptive (OC) cycle reduce menopausal symptoms in perimenopausal OC users?
    Bielanski TE
    J Fam Pract; 2001 Oct; 50(10):838. PubMed ID: 11674879
    [No Abstract]   [Full Text] [Related]  

  • 2. A scheme of combined oral contraceptives for women more than 40 years old.
    Blümel JE; Castelo-Branco C; Binfa L; Aparicio R; Mamani L
    Menopause; 2001; 8(4):286-9. PubMed ID: 11449087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Estradiol and estriol in the treatment of climacteric symptoms. A controlled trial].
    Bennedsen H; Nielsen JV
    Ugeskr Laeger; 1979 May; 141(22):1471-7. PubMed ID: 377743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of low-dose oral contraceptives (with low-doses of ethinyl estradiol), widely used in practice].
    Nalbanski B; Tsekova K; Ivanov S
    Akush Ginekol (Sofiia); 2001; 41 Suppl 4():20-3. PubMed ID: 11519317
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
    Buckler H; Al-Azzawi F;
    BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.
    Schlaff WD; Lynch AM; Hughes HD; Cedars MI; Smith DL
    Am J Obstet Gynecol; 2004 Apr; 190(4):943-51. PubMed ID: 15118618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density.
    Gambacciani M; Cappagli B; Lazzarini V; Ciaponi M; Fruzzetti F; Genazzani AR
    Maturitas; 2006 May; 54(2):176-80. PubMed ID: 16332417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
    Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
    J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
    Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW
    Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
    Kaunitz AM; Portman DJ; Hait H; Reape KZ
    Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
    Coffee AL; Kuehl TJ; Willis S; Sulak PJ
    Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
    Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
    Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
    White T; Ozel B; Jain JK; Stanczyk FZ
    Contraception; 2006 Oct; 74(4):293-6. PubMed ID: 16982228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of a new oral contraceptive containing drospirenone.
    Shulman LP
    J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Triella: a French multicenter double blind clinical study].
    Castaigne JP
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):445-53. PubMed ID: 12280213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.